Eurostars grant awarded to international consortium for development of novel treatment for clotting disorders

Published: 18-Jan-2016 Featured companies: Abzena
Research & Development

Consortium includes Antitope, a subsidiary of Abzena


A grant for €1.9m has been awarded under the Eurostars programme to a consortium that comprises a subsidiary of Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products.

This subsidiary, Antitope, a provider of immunogenicity assessment, protein engineering to create humanised antibodies and deimmunised therapeutic proteins, and cell line development, joins Dutch biopharmaceutical companies Prothix and Aristi Biotech, the University Medical Centre Utrecht (UMCU, the Netherlands) and GenOway, a French biotechnology firm.

The consortium is developing a novel treatment for clotting disorders, targeting antithrombin III, a protein which inhibits blood clotting. Members will provide their expertise to produce humanised monoclonal antibody candidates that bind antithrombin III, undertake preclinical proof of concept studies and develop a cell line for the manufacture of the selected lead candidate. This novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia, the consortium said.

Neil Butt, VP Business Development, Abzena, said: 'Applying our Composite Human Antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients.'

Featured companies

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or...
See more

You may also like

Research & Development

Abzena launches an analytical platform to accelerate antibody development

Read more
The standardised and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs

Trending Articles

  1. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Cresset creates new Vice President role to lead its AI strategy Dr Mutlu Dogruel joins from Microsoft, where he was responsible for empowering organisations to implement scalable AI solutions into their workflow
  5. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs

Relevant companies

See more

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Abzena launches an analytical platform to accelerate antibody development

The standardised and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs
Drug Delivery

Abzena launches AbZelect platforms for improving cell line development efficiency on the pathway to IND

The platforms will enable Abzena to rapidly progress their customer’s complex biologic drug programs towards clinical trials while de-risking the journey to IND application
Research & Development

The fine art of drug formulation

When it comes to pharmaceuticals, formulation development is like a finely tuned art form; the scientific understanding of a drug’s intrinsic properties must be balanced with the practical challenges of delivering it. This process, often overshadowed by the more dramatic aspects of drug discovery, plays a pivotal role in transforming promising compounds into viable and effective medications
Research & Development

Abzena partners with FDA on publication demonstrating the benefits of the MAPPs assay for immunogenicity

Abzena, has coauthored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design superior antibody and biologics with a higher chance of a successful outcome in patients
Research & Development

Abzena Partners with ProteoNic to offer enhanced CHO cell line platform for complex biologics

Premium vector technology will improve the production of high-yielding mammalian cell lines
Research & Development

Abzena opens biologics testing lab in California

Tighter control of timelines will be possible at the facility, alongside rigorous evaluation of each integrated programme to provide appropriate data
Ingredients

Bispecific antibodies: an exciting new class of emerging therapeutics

Since 2015, when the first bispecific received US FDA approval, these game-changing antibodies have rocketed in popularity<sup>1</sup>, reports Simon Keen, VP of Cell Line Development at Abzena
Subscribe now